Pan-cancer whole-genome comparison of primary and metastatic solid tumours.

Martínez-Jiménez F, Movasati A, Brunner SR, Nguyen L, Priestley P, Cuppen E, Van Hoeck A. · 2023

Read Pan-cancer whole-genome comparison of primary and metastatic solid tumours. by Martínez-Jiménez F, Movasati A, Brunner SR, Nguyen L, Priestley P, Cuppen E, Van Hoeck A. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10247378.txt.

Introduction

Martínez-Jiménez and colleagues compare the whole genomes of primary and metastatic solid tumors across many cancer types, in a 2023 study. Cancer that has spread, called metastatic cancer, is what usually kills patients. Yet most genome studies sample early tumors before spread, so the changes that come with spread were poorly mapped.

The team compared thousands of tumor genomes from both stages. They describe which changes appear early and which arise or grow during spread and treatment. The map helps explain how cancers advance and where new treatments might intervene.

Catalog record

CREATORMartínez-Jiménez F, Movasati A, Brunner SR, Nguyen L, Priestley P, Cuppen E, Van Hoeck A.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE104 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10247378

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Pan-cancer whole-genome comparison of primary and metastatic solid tumours By Francisco Martínez-Jiménez, Ali Movasati, Sascha Remy Brunner, Luan Nguyen, Peter Priestley, Edwin Cuppen, Arne Van Hoeck Published in: Nature DOI: 10.1038/s41586-023-06054-z ABSTRACT Abstract Metastatic cancer remains an almost inevitably lethal disease1–3. A better understanding of disease progression and response to therapies therefore remains of utmost importance. Here we characterize the genomic differences between early-stage untreated primary tumours and late-stage treated metastatic tumours using a harmonized pan-cancer analysis (or reanalysis) of two unpaired primary4 and metastatic5 cohorts of 7,108 whole-genome-sequenced tumours. Metastatic tumours in general have a lower intratumour heterogeneity and a conserved karyotype, displaying only a modest increase in mutations, although frequencies of structural variants are elevated overall. Furthermore, highly variable tumour-specific contributions of mutational footprints of endogenous (for example, SBS1 and APOBEC) and exogenous mutational processes (for example, platinum treatment) are present. The majority of cancer types had either moderate genomic differences (for example, lung adenocarcinoma) or highly consistent genomic portraits (for example, ovarian serous carcinoma) when comparing early-stage and late-stage disease. Breast, prostate, thyroid and kidney renal clear cell carcinomas and pancreatic neuroendocrine tumours are clear exceptions to the rule, displaying an extensive transformation of their genomic landscape in advanced stages. Exposure to treatment further scars the tumour genome and introduces an evolutionary bottleneck that selects for known therapy-resistant drivers in approximately half of treated patients. Our data showcase the potential of pan-cancer whole-genome analysis to identify distinctive features of late-stage tumours and provide a valuable resource to further investigate the biological basis of cancer and resistance to therapies. Subject terms: Mutation, Metastasis, Cancer genomics, DNA damage and repair MAIN Metastatic spread involves tumour cell detachment from a primary tumour, colonization of a secondary tissue and growth in a hostile environment1,2. Advanced metastatic tumours are frequently able to resist aggressive treatment regimes6. Despite the many efforts to understand these phenomena3,7–9, we still have limited knowledge of the contribution of genomic changes that equip tumours with these extraordinary capacities. Thus, it is essential to characterize genomic differences between primary and metastatic cancers and quantify their effect on therapy resistance to understand and harness therapeutic interventions that establish more effective and more personalized therapies10. Although extensive whole-genome analyses of primary or metastatic tumour types have been conducted4,5, large-scale comparative studies between the two tumour stages remain limited due to the logistical challenges associated with obtaining pan-cancer cohorts of primary and metastatic cancers. To circumvent this issue, most comparison studies have relied on unpaired whole-exome data or have adopted more targeted approaches with a specific focus on driver gene landscapes11–13. However, these efforts have frequently involved separated processing pipelines for primary and metastatic cohorts, complicating the analysis of genomic features that are highly sensitive to the selected data-processing strategy14,15. A recent study that uniformly analysed more than 25,000 tumours16 has provided a comprehensive overview of the genomic differences, driver alteration patterns and organotropism using clinical gene-panel sequencing as a base. However, this genomic analysis approach prevented the exploration of the full spectrum of genomic alterations that have a role in tumorigenesis, such as structural variation and mutational scarring. HARMONIZED WHOLE-GENOME-SEQUENCED TUMOURS Here we created a uniformly processed whole-genome-sequenced (WGS) inventory of 7,108 matched tumour and normal genomes from two unpaired primary and metastatic cohorts. We first collated the Hartwig Medical Foundation (Hartwig) dataset5, which included 4,784 samples from 4,375 patients with metastatic cancers. Then, we reprocessed 2,835 primary tumour samples from the Pan-Cancer Analysis of Whole Genomes (PCAWG) consortium4 using the open-source Hartwig analytical pipeline5,17 to harmonize somatic calling and annotations of events, and to eliminate processing biases (Extended Data Fig. 1 and Supplementary Table 1). Reassuringly, per-sample comparison of the number of single-base substitutions (SBSs), double-base substitutions (DBSs), indels (IDs) and structural variants (SVs) revealed a strong agreement between our results and the consensus calls originally generated by the PCAWG consortium (Supplementary Note 1). In addition, our processing pipeline strategy was minimally affected by differences in sequencing coverage, enabling a reasonable comparison of WGS samples from heterogeneous sources (Supplementary Note 1). A total of 7,108 tumour samples from 71 cancer types met the processing pipeline quality standards (Methods and Extended Data Fig. 1a) and constitutes one of the largest publicly available datasets of WGS tumours. [Figure: Cohort overview and global genomic features.a) Workflow of the unified processing pipeline used in this study for Hartwig (left) and PCAWG (right) WGS samples. First, PCAWG tumor and matched normal raw sequencing files were gathered and re-processed using the Hartwig tumor analytical pipeline. Next, the output of tumor samples that were correctly processed by the pipeline were further subjected to a strict quality control filtering. As a result, a total of 7,108 samples from 71 cancer types compose the harmonized dataset. 5,365 patient tumor samples from 23 cancer types with sufficient representation in both primary and metastatic datasets were selected for this study. b) Tumor clonality according to the metastatic biopsy location in kidney renal clear cell carcinoma, lung adenocarcinoma, prostate carcinoma and skin melanoma. N, number of samples in the group. p, two-sided Mann-Whitney p-value. Box-plots: center line, median; box limits, first and third quartiles; whiskers, lowest/highest data points at first quartile minus/plus 1.5× IQR. c) Left, similar to Fig. 1d only including non-WGD tumors. Right, similar to Fig. 1e for non-WGD tumors. d) Equivalent to c), but limited to WGD tumors. ‘*’, two-sided Mann-Whitney adjusted p-value < 0.01 for continuous variables and two-sided Fisher’s exact test adjusted p-value < 0.01 for TP53.] We next focused on 23 cancer types from 14 tissues with sufficient sample representation, comprising 5,365 tumour samples (1,914 primary and 3,451 metastatic) to explore genomic differences between primary and metastatic tumours (Fig. 1a and Extended Data Fig. 1a). Within this dataset, patients with metastatic tumours were slightly older at biopsy than patients with primary tumours (mean of 1.67 years older across all cancer types), although patients with metastatic prostate and thyroid carcinomas, and diffuse large B cell lymphoma were markedly older than their primary counterparts. Consistent gender proportions were observed across all cancer types except for thyroid adenocarcinomas (metastatic: 72% male and 28% female; primary: 25% male and 75% female). Treatment information was available for 83.7% of patients with metastatic tumours, which is essential to gauge specific treatment-induced contributions to genomic differences between primary and metastatic tumours (Fig. 1a). Finally, biopsy locations were annotated for 84.2% of patients with metastatic tumours (12.2% from metastatic lesions in the primary tissue (local), 16.2% in lymph nodes and 55.7% in distant locations) and displayed a highly tumour-type-specific distribution pattern, probably reflecting both the dissemination patterns of the tumours and the accessibility for safe clinical sampling. [Figure: Database overview and global genomic features.a, Anatomical location of the 23 cancer types, ordered by tissue or origin, included in this study. From left to right: sample size, age at biopsy, gender, treatment type and biopsy site of the cohort with metastatic tumours. CNS, central nervous system. The image in a was created using BioRender (https://biorender.com). b, Mean percentage of clonal mutations in primary (x axis) and metastatic (y axis) tumours. The dots are coloured according to the log2 of the clonality ratio (metastatic divided by primary). The size of the dots is proportional to the

Read the complete text